Aim: Gordon et al. investigated the efficacy and safety of risankizumab [an anti?interleukin (IL)?23p19 biologic] compared with ustekinumab (anti?IL?12/23p40) and placebo in patients with moderate?to?severe chronic plaque psoriasis.
The purpose of this study is to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) for the treatment of moderate to severe chronic plaque psoriasis in adult patients.
Objective: We investigated the similarities and differences in molecular and histopathologic profiles in skin lesions from patients with psoriasis receiving risankizumab versus ustekinumab at an early time point.
We aimed to assess the efficacy and safety of risankizumab compared with placebo or ustekinumab in patients with moderate-to-severe chronic plaque psoriasis.
This is a randomized double blind, double dummy, placebo and active comparator controlled, parallel design study that is being performed to assess the safety and efficacy of risankizumab (BI 655066) to support registration...
Psoriasis is a common chronic immune-mediated skin disease, with systemic involvement and significant impact in patients' quality of life.
AbbVie presented new positive results from the pivotal Phase III ultIMMa-1 and ultIMMa-2 replicate clinical trials that evaluated the safety...
This is a randomized double blind, double dummy, placebo and active comparator controlled, parallel design study that is being performed to assess the safety and efficacy of BI 655066/ABBV-066...
AbbVie has filed ABBV 066 (risankizumab) with the FDA, seeking approval for its use to treat moderate-to-severe plaque psoriasis. The...
We aimed to compare the efficacy and safety of risankizumab with adalimumab in patients with moderate-to-severe plaque psoriasis.